SOURCE: Seegene


April 22, 2015 08:22 ET

Seegene to Attend ECCMID 2015 Annual Meeting

Company to Hold a Symposium of Key Opinion Leaders on the Clinical Impacts of HPV Genotyping; Symposium to Showcase Clinical Evidences That Seegene's Anyplex™ II HPV HR Detection Is a More Effective Solution for Primary HPV Screening in Cervical Cancer Prevention and Patient Management

CONCORD, CA and SEOUL, KOREA--(Marketwired - Apr 22, 2015) - Seegene Inc. (KOSDAQ: 096530), a leading developer of multiplex PCR technologies, today announced that it is attending the 25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) from April 25 to 28 at the Bella Center in Copenhagen, Denmark.

The company will feature its comprehensive Allplex™ family of infectious disease panels at its booth (#254) that includes respiratory infection full panels, gastrointestinal infection full panels, and sexually transmitted infection full panels. Allplex™ panel tests are based on Seegene's innovative MuDT™ technology that enables simultaneous detection and quantification of multiple targets in a single fluorescence channel, without melting curve analysis.

On Monday, April 27, the company will also hold the "Seegene Integrated Symposium" where leading cervical cancer experts will discuss the increasing importance of high-risk HPV DNA testing as a primary screening test, and demonstrate overwhelming clinical evidences that Seegene's Anyplex™ II HPV HR Detection, which identifies 14 individual high-risk types of human papillomavirus, is a more effective solution to be used routinely for primary screening in cervical cancer prevention and patient management.

The Seegene Integrated Symposium: HPV Genotyping, Challenge for the Cervical Cancer Screening and Prevention
Time 16:00~18:00
Location: Hall G (C1-M3)

Featured speakers include:

  • Dr. Chris JLM Meijer: Vrije University Medical Center, Department of Pathology, The Netherlands (Seegene Chair)
  • Dr. Karl Ulrich Petry: Klinikum Wolfsburg, Department of OBGYN & Gynecologic Oncology, Germany
  • Dr. Peter Snijders: Vrije University Medical Center, Department of Pathology, The Netherlands
  • Dr. Cosette M. Wheeler: University of New Mexico, Department of Pathology, the United States
  • Dr. Rosaria Santangelo: Institute of Microbiology, Catholic University School of Medicine, Italy
  • Dr. Snjezana Zidovec Lepej: University Hospital for Infectious Diseases, Department of Molecular Diagnostics and Flow Cytometry, Croatia (ESCMID Chair)

About Seegene
Seegene is the world's leading developer of multiplex molecular technologies and multiplex clinical molecular diagnostics (M-MoDx). Seegene's core enabling technologies -- ACP™, DPO™, READ™, TOCE™, mTOCE™ and MuDT™ -- are the foundation for M-MoDx tests that can simultaneously detect multiple targets with high sensitivity, specificity and reproducibility. Seegene's products detect multi-pathogens with great reliability and throughput, ultimately providing the most economical basis for saving time, labor and cost. Seegene's mission is to maintain leadership in molecular diagnostics for infectious diseases, genetics, pharmacogenomics, and oncology using innovative proprietary technologies.

For more information please visit or call +301-762-9066.

Contact Information